thiazoles has been researched along with vorinostat in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kouketsu, A; Kurotaki, M; Maruyama, S; Matsuura, A; Miyata, N; Nagano, Y; Nakagawa, H; Suzuki, T | 1 |
| Blümcke, I; Buslei, R; Eyüpoglu, IY; Fahlbusch, R; Hahnen, E; Lüders, M; Savaskan, NE; Siebzehnrübl, FA; Tränkle, C; Weller, M; Wick, W | 1 |
| Balasis, M; Bali, P; Bhalla, K; Estrella, V; Fiskus, W; Herger, B; Kumaraswamy, S; Lee, F; Pranpat, M; Rao, R; Richon, V; Rocha, K | 1 |
| Bowers, A; Bradner, JE; Schreiber, SL; Taunton, J; West, N; Williams, RM | 1 |
| Dino, PM; Forman, SJ; Jove, R; Kirschbaum, MH; Kowolik, CM; Kretzner, L; Scuto, A; Ventura, P; Wu, J; Yen, Y | 1 |
| Caci, E; Esposito, AI; Galietta, LJ; Pedemonte, N; Pfeffer, U; Sondo, E; Tomati, V | 1 |
| Orlowski, RZ | 1 |
| Lancet, JE | 1 |
2 review(s) available for thiazoles and vorinostat
| Article | Year |
|---|---|
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
6 other study(ies) available for thiazoles and vorinostat
| Article | Year |
|---|---|
Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Topics: Acetylation; Antineoplastic Agents; Binding Sites; Binding, Competitive; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Models, Molecular; Structure-Activity Relationship; Thiazoles; Vorinostat | 2005 |
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
Topics: Acetylation; Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Dose-Response Relationship, Drug; Flow Cytometry; Glioma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Neoplasm Transplantation; Organ Culture Techniques; Peptides, Cyclic; Rats; Rats, Inbred F344; Rats, Wistar; Tetrazolium Salts; Thiazoles; Time Factors; Vorinostat | 2005 |
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured; Vorinostat | 2006 |
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.
Topics: Cell Line, Tumor; Cell Proliferation; Depsipeptides; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship; Sulfhydryl Compounds; Thiazoles; Vorinostat | 2008 |
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cyclohexanecarboxylic Acids; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, myc; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Lymphoma; MicroRNAs; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Telomerase; Thiazoles; Vorinostat | 2011 |
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
Topics: Aminacrine; Bacterial Proteins; Benzamides; Cell Line; Cell Membrane; Chlorides; Ciclopirox; Cold Temperature; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Gene Expression Profiling; Gene Expression Regulation; Humans; Hydroxamic Acids; Luminescent Proteins; Mutation; Piperazines; Protein Transport; Pyridones; Quinazolines; Thiazoles; Vorinostat | 2011 |